Tesofensine is sold and discussed alongside weight-management peptides, so it
belongs in this library — but it is important to be clear about what it is.
Chemical identity & structure.
Tesofensine is a small molecule, not a peptide. Chemically it is a synthetic
compound that acts on neurotransmitter transporters. It is grouped with peptides
here only because the research-compound market sells it in the weight-management
category; it has no structural relationship to the peptides in this library.
Mechanism of action.
Tesofensine is a triple monoamine-reuptake inhibitor — it inhibits the
reuptake of noradrenaline, dopamine, and serotonin, raising the levels of these
neurotransmitters in the brain. The appetite-suppressing and weight effects are
attributed to this central monoaminergic action. This is a fundamentally
different mechanism from the incretin (GLP-1) peptides.
Key research findings.
Tesofensine was originally investigated for neurological conditions, where
weight loss was noted as a side effect — which redirected interest toward
obesity. Clinical trials for obesity reported meaningful weight loss. Because it
raises monoamines, the trial data also characterized effects on heart rate,
blood pressure, and mood-related parameters, which are central to its
risk profile.
The research / citation base.
Tesofensine is not approved as a weight-loss drug in major markets, though
it has been the subject of clinical trials and continued development in some
regions. Its evidence base is genuine clinical research, but its cardiovascular
and central-nervous-system effects are a real reason for caution.
Human clinical trial data.
In the phase II randomised, double-blind, placebo-controlled trial by Astrup et al. (2008), 203 obese patients on an energy restricted diet were randomly assigned to tesofensine at one of three dose levels or placebo for 24 weeks (PubMed).
Quality & sourcing notes.
As a small molecule, identity and purity should be documented on a
batch-specific COA using methods appropriate to a small molecule (not peptide
mass spectrometry).
*Research-use note: Educational summary of published research. Tesofensine is a
non-approved investigational compound with notable cardiovascular/CNS effects;
this is research context only and not medical advice.*